Compare Mesoblast Limited (MESO) vs Energy Select Sector SPDR Fund (XLE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Energy Select Sector SPDR Fund — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.75B), while Energy Select Sector SPDR Fund trades at $64.96 (market cap $40.84B). The key difference: Energy Select Sector SPDR Fund is far larger — about 23.3× Mesoblast Limited's market cap, and Energy Select Sector SPDR Fund is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Energy Select Sector SPDR Fund for 67 Days on average.
| MESO | XLE | |
|---|---|---|
Market Cap | $1.75B | $40.84B |
Volume | 239,027 | 50,409,268 |
Sector | Health | — |
52-Week High | $20.96 | $65.93 |
52-Week Low | $13.19 | $42.61 |
Typical Hold Time | 14 Days | 67 Days |
Enterprise Value | $1.83B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
XLE trades at $63.38, down 0.58% with a bullish technical signal from moving averages. The ETF faces mixed sentiment amid oil price volatility, with recent news highlighting Middle East tensions and strategic reserve releases. Key support sits at $62-63 while resistance levels cluster around $64-65. The fund's 91% oil and gas concentration makes it highly sensitive to crude price movements.
Outlook remains tied to oil market dynamics with geopolitical risks and Fed policy as key drivers. The bullish technical setup suggests near-term upside potential, though energy sector volatility requires careful risk management given the concentrated exposure to commodity prices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Energy Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as energy companies by the GICS®, including securities of companies from the following industries: oil, gas and consumable fuels; and energy equipment and services. It is non-diversified.
Read more on XLE →
